



DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health

National Institute on Drug Abuse; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse.

This will be a hybrid meeting held in-person and virtually and will be open to the public, as indicated below, with attendance limited to space available. Individuals who plan to attend in-person or view the virtual meeting and need special assistance such as sign language interpretation or other reasonable accommodations, should notify Dr. Gillian Acca via email at gillian.acca@nih.gov five days in advance of the meeting. The open session of the meeting can be accessed by registering at the following link: <https://nida.nih.gov/about-nida/advisory-boards-groups/national-advisory-council-drug-abuse-nacda/national-advisory-council-agenda>.

A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council on Drug Abuse

Date: September 9, 2025

Closed: 10:30 AM to 11:45 AM

Agenda: To review and evaluate grant applications

Open: 1:00 PM to 5:00 PM

Agenda: Presentations and other business of the Council

Meeting Format: Hybrid Meeting

Place: Neuroscience Center, Conference Room 1145/1155
National Institutes of Health
6001 Executive Boulevard
Rockville, MD 20852
(In-Person and Virtual Meeting)

Contact Person: Susan R.B. Weiss, PHD
Director
Division of Extramural Research
Office of the Director
National Institute on Drug Abuse, NIH
Three White Flint North, RM 09D08
11601 Landsdown Street
Bethesda, MD 20852
301-443-6480
sweiss@nida.nih.gov

Contact Person: Gillian Acca, PHD
Health Scientist Administrator
Division of Extramural Research
Office of Extramural Policy
National Institute on Drug Abuse, NIH
Three White Flint North, RM 09C70
11601 Landsdown Street
Bethesda, MD 20852
301-827-5863
gillian.acca@nih.gov

Any interested person may file written comments with the committee by forwarding the statement to Dr. Gillian Acca via email at gillian.acca@nih.gov. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at <https://www.nih.gov/about-nih/visitor-information/campus-access-security> for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: August 12, 2025.

Bruce A. George,
Program Analyst,
Office of Federal Advisory Committee Policy.

[FR Doc. 2025-15505 Filed: 8/14/2025 8:45 am; Publication Date: 8/15/2025]